COVID-19 Vaccine Candidates in Development

Monoclonal antibodies that are in development for COVID-19 treatment and T cells that target the virus—and may help them recover.

His team responses to SARS-CoV-2 and the implications for vaccine development. His team work cooperatively with companies, governments, and international bodies to vaccine equity and access. Through Gavi, the WHO, CEPI, and support for a Institute of Thailand to conduct trials in Southeast Asia.

collaboration with Kalbe, an Indonesian company, and the National Vaccine supporting companies to test COVID-19 vaccines overseas. Genexine has initiated a efficacy trials of COVID-19 vaccines. Rather, the government is considering and is selecting the best candidate to develop.

biosimilar manufacturers, has identified neutralizing antibodies against SARS-CoV-2 preclinical testing. Celltrion, one of the world’s leading monoclonal antibody and concept) and GI Innovation (with a unique CD80-IL2R adjuvant) are entering

Other biotechnology companies such as GenoFocus (working on a bacterial spore and is selecting the best candidate to develop. Our part, the International Vaccine Institute (IVI) will not pursue its own vaccine development. The Bill & Melinda Gates Foundation is funding a Korean company, including IVI, developed a SARS-CoV-2 DNA vaccine candidate that entered human vaccines. Genexine and a team of academic and government partners, expedite vaccine development across platforms. We are working with Sumagen and but instead will work with companies, research institutes, and universities to


to work, shops, or church—is inconvenient, but not intolerable. Despite the Korean percent of cases without clear attribution were, by and large, achieved. But because of intensive efforts to control further spread, tests and identified over 300 people with SARS-CoV-2, as successive new waves of infections were seeded.